News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (343 of 400). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (15 of 400). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (42 of 400). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 291 of 400 items have one.
FDA approves drug for infantile-onset Niemann-Pick type C after analysis finds longer survival
Researchers at the National Institutes of Health (NIH) and their collaborators at Beren Therapeutics, Thousand Oaks, California, have developed a treatment for infants with Niemann-Pick type C (NPC) disease…
Read at Medical Xpress →Tau Therapy Shows Continued Benefit at 2 Years in Alzheimer's
(MedPage Today) -- Diranersen, an investigational antisense oligonucleotide therapy that targets tau, continued to show benefits for 96 weeks, data from the open-label extension of the phase II CELIA trial suggested. At 2 years, diranersen continued...
Free to read? Not known for this outlet.
Read at MedPage Today →Erectile Dysfunction Drug Shows Mixed Results in Alzheimer's
(MedPage Today) -- Mirodenafil (known as AR1001), an oral phosphodiesterase-5 inhibitor approved in South Korea to treat erectile dysfunction, showed mixed results in people with early Alzheimer's disease in the phase III POLARIS-AD trial. The...
Free to read? Not known for this outlet.
Read at MedPage Today →Oxaloacetate may ease cognitive impairment after cancer treatment
A nutritional supplement that contains oxaloacetate may benefit breast cancer survivors who experience persistent cognitive impairment after treatment, results of a small pilot study suggest. …
Free to read? Not known for this outlet.
Read at Healio →One-hour test could help doctors better spot memory problems
With the expected worldwide rise in all-cause dementia to approximately 152.8 million by the year 2050 and the potential for disease-modifying therapies such as anti-amyloid monoclonal antibodies…
Read at Medical Xpress →Five lifespan-extending treatments boost the same antioxidant in mice
Aging is about far more than wrinkles and gray hair, despite what social media and advertisements might have us believe. The real concern lies beneath the surface, where the biology of aging is intertwined with a host of diseases…
Read at Medical Xpress → Archived copy (13 Nov 2026), Internet ArchiveChristchurch mutation points to potential gene therapy avenue for Parkinson's
A rare genetic mutation may protect against developing Parkinson's disease and Lewy body dementia, a new study from researchers at Oregon Health & Science University suggests.
Read at Medical Xpress → Archived copy (12 Nov 2026), Internet ArchiveSTAT+: Dutch antitrust regulators probe Biogen over test for its MS drug
Dutch antitrust regulators are investigating allegations that Biogen may have abused its dominant position in the market for MS treatments and associated blood tests.
May need a subscription The publisher's page marks this article as not free to read (checked 11 Nov 2026).
Read at STAT News → Archived copy (11 Nov 2026), Internet ArchiveStudy challenges long-held fears about overactive bladder drugs and dementia
New research published in JAMA Network Open finds anticholinergic medications, commonly prescribed for overactive bladder (OAB), may not increase dementia risk after all compared to beta-3 agonists, the newer drug class that has been presumed to be safer for the brain.
Read at Medical Xpress →Common osteoporosis drugs linked to 24% lower dementia risk in major study
A massive study of more than 120,000 older adults suggests that common osteoporosis drugs may reduce the risk of Alzheimer’s disease and other dementias by up to 24%. …
Read at ScienceDaily → Archived copy (9 Nov 2026), Internet ArchiveEngineered protein that cuts Alzheimer's-linked brain deposits opens potential therapeutic avenue
A KAIST-led research team has found that a protein involved in gene regulation can suppress the harmful aggregation of amyloid-beta, a peptide associated with Alzheimer's disease. The approach also reduced the toxicity of protein aggregates that had already formed.
Read at Medical Xpress → Archived copy (15 Nov 2026), Internet ArchiveSTAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug
Shares of ProMis Neurosciences, developer of a treatment for Alzheimer’s disease, sold off sharply last week. A closer look at the reason why — and whether it holds up.
May need a subscription The publisher's page marks this article as not free to read (checked 6 Nov 2026).
Read at STAT News → Archived copy (6 Nov 2026), Internet ArchiveAn anti-aging drug may help protect the brain before Alzheimer's symptoms begin
A surprising new study suggests that an anti-aging drug could help protect people genetically predisposed to Alzheimer's disease. Researchers found that just four weeks of low-dose rapamycin improved brain blood flow in healthy middle-aged adults carrying the high-risk APOE4…
Read at ScienceDaily → Archived copy (6 Nov 2026), Internet ArchiveCholesterol transport protein emerges as possible target for Parkinson's treatment
Parkinson's disease (PD) is a neurodegenerative condition that causes the progressive loss of dopamine-producing neurons in a brain region called the substantia nigra. Its characteristic symptoms include tremors, slowed movements, rigid muscles and difficulties with balance.
Read at Medical Xpress → Archived copy (3 Nov 2026), Internet ArchiveScientists discover new Alzheimer’s drug that repairs DNA damage and reduces brain inflammation
Scientists have discovered that a drug originally developed for spinal cord injuries can tackle several key features of Alzheimer’s disease, including DNA damage and inflammation. …
Read at ScienceDaily → Archived copy (6 Nov 2026), Internet ArchiveReview board improves access to anti-amyloid therapies
SAN DIEGO — As demand increases for anti-amyloid therapy that can slow the progression of Alzheimer’s disease, it will be crucial for healthcare systems to find more efficient ways to review referrals for treatment, according to a presenter. …
Free to read? Not known for this outlet.
Read at Healio → Archived copy (29 Oct 2026), Internet ArchiveWireless neural chip tracks brain changes in real time after Alzheimer's drug administration
A joint research team led by KAIST has used a small, implantable neural chip to wirelessly monitor real-time changes in a neurotransmitter involved in memory and learning after an Alzheimer's drug has been administered. …
Read at Medical Xpress →Treatment revives old liver cells in lab study, may help prevent Alzheimer's and heart disease
The liver's job of clearing harmful substances from the body is so essential that the organ may have implications for addressing unexpected diseases, including Alzheimer's and heart disease. …
Read at Medical Xpress → Archived copy (7 Nov 2026), Internet ArchiveExperimental treatment selectively reduces harmful protein in lab models of rare inherited brain disorder
Researchers from DZNE and the Hertie Institute for Clinical Brain Research (HIH) at the University of Tübingen, together with experts from Bonn, London and Portugal…
Read at Medical Xpress →Search for Alzheimer's drug unexpectedly finds possible biomarker
Researchers developed a drug for Alzheimer's disease and then discovered that the molecule already exists in human blood and is found at lower levels in cognitively impaired people. Now the authors are exploring the peptide as a biomarker as well as a treatment.
Read at Medical Xpress →Brain PET scans help select and monitor patients for new Alzheimer's drugs
Nuclear medicine is playing an increasingly important role in the diagnosis and treatment of Alzheimer's disease, helping clinicians visualize the biological changes associated with the condition and guide decisions about new therapies. …
Read at Medical Xpress →New drug-delivery method offers promise in fight against neurodegenerative diseases
For patients battling neurodegenerative diseases like ALS, Parkinson's, Alzheimer's and other dementias, delivering disease-fighting antibody drugs directly to the brain has proven to be a difficult task. …
Read at Medical Xpress → Archived copy (25 Oct 2026), Internet ArchiveWho gets Alzheimer's drugs? Race, vulnerability and health status shape access
The first disease-modifying drugs for Alzheimer's disease offer patients the ability to slow cognitive decline by targeting amyloid plaques in the brain. But a new study suggests that not all patients have the same opportunity to receive these treatments.
Alzheimer's Drug ARIA Monitoring: Real-World Study Results
(MedPage Today) -- Rates of amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease patients treated with lecanemab (Leqembi) in the real world were consistent with those seen in clinical trials, data from the LEADER study showed....
Free to read? Not known for this outlet.
Read at MedPage Today → Archived copy (17 Oct 2026), Internet ArchiveDrug combination that reduces oxygen levels in tissues improves Parkinson's symptoms in mice
In a new study, Broad Institute researchers report that two small-molecule chemicals that reduce oxygen delivery to cells improved symptoms of neurodegeneration in a mouse model of Parkinson's disease. …
Read at Medical Xpress →The hidden math of Alzheimer's could point to new treatments
Mathematics may hold unexpected clues to understanding Alzheimer’s disease. Scientists have developed a model showing how common metals like copper and zinc may influence the buildup of proteins associated with the disease, while also exploring possible ways to stop…
Read at ScienceDaily → Archived copy (12 Oct 2026), Internet ArchiveStarting Alzheimer's treatment earlier increases benefits to patients and society
New treatments that can slow the progression of Alzheimer's disease could provide significant lifetime benefits to patients and society, with even greater benefits when initiated earlier, according to new research from the USC Schaeffer Center for Health Policy & Economics.
Read at Medical Xpress → Archived copy (7 Oct 2026), Internet ArchiveClinical trial tests AI-assisted medication device for older adults with memory loss
Marianne Blake has lived in the same home for nearly half a century. She plays bridge regularly, drives to her hair appointments and, at 88 years old, enjoys her independence.
Read at Medical Xpress →STAT+: Nobel-winning optogenetics research has led to experimental treatments for blindness and Alzheimer’s
Optogenetics is now the foundational way through which we are able to understand how the brain…
Why it matters: Optogenetics research has led to experimental treatments for blindness and Alzheimer's, serving as a foundational way to understand brain function.
May need a subscription Based on the outlet (STAT), not a check of this article.
Read at STAT News → Archived copy (5 Oct 2026), Internet ArchiveDrugs are widely used to sedate dementia patients. Her sons wanted to keep her off them
Potent sedating medications are often used on agitated people with dementia in long-term care facilities despite federal efforts to discourage them. A clash over whether to drug a Michigan woman illuminates the wrenching decisions families and guardians face.
Why it matters: A Michigan dispute over sedating a woman with dementia shows the difficult decisions families face as care facilities widely use potent sedatives despite federal discouragement.
Read at NPR → Archived copy (8 Oct 2026), Internet ArchiveFollow new items in a feed reader: Atom feed.
Last updated